Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ross Stuart Berkowitz, M.D.

Co-Author

This page shows the publications co-authored by Ross Berkowitz and Colleen Feltmate.
Connection Strength

3.222
  1. Clinical characteristics of persistent gestational trophoblastic neoplasia after partial hydatidiform molar pregnancy. J Reprod Med. 2006 Nov; 51(11):902-6.
    View in: PubMed
    Score: 0.342
  2. Human chorionic gonadotropin follow-up in patients with molar pregnancy: a time for reevaluation. Obstet Gynecol. 2003 Apr; 101(4):732-6.
    View in: PubMed
    Score: 0.267
  3. Advances in the understanding of placental site trophoblastic tumor. J Reprod Med. 2002 May; 47(5):337-41.
    View in: PubMed
    Score: 0.250
  4. Placental site trophoblastic tumor: a 17-year experience at the New England Trophoblastic Disease Center. Gynecol Oncol. 2001 Sep; 82(3):415-9.
    View in: PubMed
    Score: 0.239
  5. Extramammary Paget Disease of the Vulva: A Case Series Examining Treatment, Recurrence, and Malignant Transformation. Int J Gynecol Cancer. 2018 03; 28(3):632-638.
    View in: PubMed
    Score: 0.187
  6. Same-Day Discharge After Laparoscopic Hysterectomy for Endometrial Cancer. Ann Surg Oncol. 2016 Jan; 23(1):178-85.
    View in: PubMed
    Score: 0.154
  7. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol. 2014 Feb; 132(2):280-6.
    View in: PubMed
    Score: 0.140
  8. Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy. J Reprod Med. 2010 Jul-Aug; 55(7-8):279-84.
    View in: PubMed
    Score: 0.110
  9. Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia. Gynecol Oncol. 2009 Feb; 112(2):353-7.
    View in: PubMed
    Score: 0.099
  10. Robotic versus open radical hysterectomy: a comparative study at a single institution. Gynecol Oncol. 2008 Dec; 111(3):425-30.
    View in: PubMed
    Score: 0.098
  11. Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia. J Reprod Med. 2008 Jul; 53(7):481-6.
    View in: PubMed
    Score: 0.096
  12. Gestational trophoblastic disease. Clin Obstet Gynecol. 2007 Mar; 50(1):112-22.
    View in: PubMed
    Score: 0.087
  13. Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas. Clin Cancer Res. 2005 Nov 01; 11(21):7651-7.
    View in: PubMed
    Score: 0.080
  14. The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey. Gynecol Oncol. 2005 Oct; 99(1):3-5.
    View in: PubMed
    Score: 0.079
  15. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol Oncol. 2004 Dec; 95(3):421-2.
    View in: PubMed
    Score: 0.075
  16. Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions. Cancers (Basel). 2021 May 03; 13(9).
    View in: PubMed
    Score: 0.058
  17. Triaging abnormal cervical cancer screening tests using p16INK4a detection by ELISA on fresh cervical samples. Am J Reprod Immunol. 2021 07; 86(1):e13394.
    View in: PubMed
    Score: 0.058
  18. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Res. 2021 01 01; 81(1):158-173.
    View in: PubMed
    Score: 0.056
  19. Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). Int J Gynecol Pathol. 2019 May; 38(3):230-240.
    View in: PubMed
    Score: 0.051
  20. Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.049
  21. Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas. J Pathol. 2018 11; 246(3):344-351.
    View in: PubMed
    Score: 0.049
  22. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov. 2018 11; 8(11):1404-1421.
    View in: PubMed
    Score: 0.049
  23. The impact of health insurance status on the stage of cervical cancer diagnosis at a tertiary care center in Massachusetts. Gynecol Oncol. 2018 07; 150(1):67-72.
    View in: PubMed
    Score: 0.047
  24. Universal Screening for Mismatch-Repair Deficiency in Endometrial Cancers to Identify Patients With Lynch Syndrome and Lynch-like Syndrome. Int J Gynecol Pathol. 2017 Mar; 36(2):115-127.
    View in: PubMed
    Score: 0.044
  25. Loss of E-cadherin disrupts ovarian epithelial inclusion cyst formation and collective cell movement in ovarian cancer cells. Oncotarget. 2016 Jan 26; 7(4):4110-21.
    View in: PubMed
    Score: 0.041
  26. Does plastic surgical consultation improve the outcome of patients undergoing radical vulvectomy for squamous cell carcinoma of the vulva? Gynecol Oncol. 2015 Apr; 137(1):60-5.
    View in: PubMed
    Score: 0.038
  27. Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma. Gynecol Oncol. 2014 Oct; 135(1):54-7.
    View in: PubMed
    Score: 0.037
  28. What is the optimal treatment for obese patients with advanced ovarian carcinoma? Am J Obstet Gynecol. 2014 Sep; 211(3):231.e1-9.
    View in: PubMed
    Score: 0.036
  29. A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer. Gynecol Oncol. 2014 Jan; 132(1):55-60.
    View in: PubMed
    Score: 0.035
  30. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery? Gynecol Oncol. 2013 Apr; 129(1):69-73.
    View in: PubMed
    Score: 0.033
  31. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012 May; 125(2):362-6.
    View in: PubMed
    Score: 0.031
  32. The epidemiology of ovarian granulosa cell tumors: a case-control study. Gynecol Oncol. 2009 Nov; 115(2):221-5.
    View in: PubMed
    Score: 0.026
  33. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007 Sep 01; 25(25):3985-90.
    View in: PubMed
    Score: 0.023
  34. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007 Feb; 31(2):161-9.
    View in: PubMed
    Score: 0.022
  35. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia among women with partial molar pregnancies. J Reprod Med. 2006 Nov; 51(11):871-4.
    View in: PubMed
    Score: 0.021
  36. Low risk of relapse after achieving undetectable HCG levels in women with partial molar pregnancy. Obstet Gynecol. 2006 Aug; 108(2):393-6.
    View in: PubMed
    Score: 0.021
  37. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy. Obstet Gynecol. 2006 Mar; 107(3):743.
    View in: PubMed
    Score: 0.020
  38. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):690-700.
    View in: PubMed
    Score: 0.020
  39. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy. Obstet Gynecol. 2005 Sep; 106(3):548-52.
    View in: PubMed
    Score: 0.020
  40. Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy. Obstet Gynecol. 2004 Sep; 104(3):551-4.
    View in: PubMed
    Score: 0.018
  41. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 2002 Apr 03; 287(13):1671-9.
    View in: PubMed
    Score: 0.016
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.